Shahram Oveisgharan1, Aron S Buchman2, Lei Yu2, Jose Farfel2, Vladimir Hachinski2, Chris Gaiteri2, Philip L De Jager2, Julie A Schneider2, David A Bennett2. 1. From Rush Alzheimer's Disease Center (S.O., A.S.B., L.Y., J.F., C.G., J.A.S., D.A.B.) and Departments of Neurological Sciences (A.S.B., L.Y., J.A.S., D.A.B.) and Pathology (J.F., J.A.S.), Rush University Medical Center, Chicago, IL; Shariati Hospital (S.O.), Tehran University of Medical Sciences, Iran; Department of Geriatrics (J.F.), University of Sao Paulo Medical School, Brazil; University Hospital (V.H.), University of Western Ontario, London, Canada; Broad Institute (P.L.D.J.), Cambridge, MA; Center for Translational & Systems Neuroimmunology (P.L.D.J.), Department of Neurology, Columbia University Medical Center, New York, NY. shahram_oveisgharan@rush.edu. 2. From Rush Alzheimer's Disease Center (S.O., A.S.B., L.Y., J.F., C.G., J.A.S., D.A.B.) and Departments of Neurological Sciences (A.S.B., L.Y., J.A.S., D.A.B.) and Pathology (J.F., J.A.S.), Rush University Medical Center, Chicago, IL; Shariati Hospital (S.O.), Tehran University of Medical Sciences, Iran; Department of Geriatrics (J.F.), University of Sao Paulo Medical School, Brazil; University Hospital (V.H.), University of Western Ontario, London, Canada; Broad Institute (P.L.D.J.), Cambridge, MA; Center for Translational & Systems Neuroimmunology (P.L.D.J.), Department of Neurology, Columbia University Medical Center, New York, NY.
Abstract
OBJECTIVE: To examine the association of the APOE ε2ε4 genotype with incident Alzheimer disease (AD), mild cognitive impairment (MCI), cognitive decline, and AD pathology in older adults. METHODS: We used data from 2,151 older adults of European ancestry who were free of dementia at baseline and underwent structured annual clinical evaluation in a longitudinal study for incident AD and MCI, and cognitive decline. Postmortem examination in decedents documented pathologic AD and quantified β-amyloid and neurofibrillary tangles. Participants were stratified into 4 groups based on APOE genotyping: ε2ε4, ε4 (ε4ε4, ε4ε3), ε2 (ε2ε2, ε2ε3), with ε3ε3 carriers serving as the reference group. We used Cox proportional hazards models to examine the association of APOE genotype with incident AD and MCI. Linear mixed-effect models were used to examine the association with cognitive decline. Logistic and linear regression models were used to examine AD pathology. All the models controlled for age, sex, and education. RESULTS: Of the 2,151 participants included in this study, ε2ε4 accounted for 2.1%, ε3/4 and 4/4 21.8%, ε2/3 and 2/2 14.0%, and ε3ε3 62.1%. We did not observe a difference in the risk of AD for ε2ε4 compared to ε3ε3. In cases without cognitive impairment at baseline, ε2ε4 carriers had an increased risk of incident MCI (hazard ratio 2.13, 95% confidence interval 1.34-3.39, p = 0.002) and a faster rate of cognitive decline (estimate -0.047, SE 0.018, p = 0.008) compared to ε3ε3 carriers. In decedents (n = 1,100), ε2ε4 showed a 3-fold increased odds of pathologic AD and a higher β-amyloid load than ε3ε3. CONCLUSION: APOE ε2ε4 genotype in older adults is associated with risk of MCI, cognitive decline, and a greater burden of AD pathology, especially β-amyloid.
OBJECTIVE: To examine the association of the APOE ε2ε4 genotype with incident Alzheimer disease (AD), mild cognitive impairment (MCI), cognitive decline, and AD pathology in older adults. METHODS: We used data from 2,151 older adults of European ancestry who were free of dementia at baseline and underwent structured annual clinical evaluation in a longitudinal study for incident AD and MCI, and cognitive decline. Postmortem examination in decedents documented pathologic AD and quantified β-amyloid and neurofibrillary tangles. Participants were stratified into 4 groups based on APOE genotyping: ε2ε4, ε4 (ε4ε4, ε4ε3), ε2 (ε2ε2, ε2ε3), with ε3ε3 carriers serving as the reference group. We used Cox proportional hazards models to examine the association of APOE genotype with incident AD and MCI. Linear mixed-effect models were used to examine the association with cognitive decline. Logistic and linear regression models were used to examine AD pathology. All the models controlled for age, sex, and education. RESULTS: Of the 2,151 participants included in this study, ε2ε4 accounted for 2.1%, ε3/4 and 4/4 21.8%, ε2/3 and 2/2 14.0%, and ε3ε3 62.1%. We did not observe a difference in the risk of AD for ε2ε4 compared to ε3ε3. In cases without cognitive impairment at baseline, ε2ε4 carriers had an increased risk of incident MCI (hazard ratio 2.13, 95% confidence interval 1.34-3.39, p = 0.002) and a faster rate of cognitive decline (estimate -0.047, SE 0.018, p = 0.008) compared to ε3ε3 carriers. In decedents (n = 1,100), ε2ε4 showed a 3-fold increased odds of pathologic AD and a higher β-amyloid load than ε3ε3. CONCLUSION: APOE ε2ε4 genotype in older adults is associated with risk of MCI, cognitive decline, and a greater burden of AD pathology, especially β-amyloid.
Authors: Guy M McKhann; David S Knopman; Howard Chertkow; Bradley T Hyman; Clifford R Jack; Claudia H Kawas; William E Klunk; Walter J Koroshetz; Jennifer J Manly; Richard Mayeux; Richard C Mohs; John C Morris; Martin N Rossor; Philip Scheltens; Maria C Carrillo; Bill Thies; Sandra Weintraub; Creighton H Phelps Journal: Alzheimers Dement Date: 2011-04-21 Impact factor: 21.566
Authors: John C Morris; Catherine M Roe; Chengjie Xiong; Anne M Fagan; Alison M Goate; David M Holtzman; Mark A Mintun Journal: Ann Neurol Date: 2010-01 Impact factor: 10.422
Authors: Chunsheng Wang; Wilkie A Wilson; Scott D Moore; Brian E Mace; Nobuyo Maeda; Donald E Schmechel; Patrick M Sullivan Journal: Neurobiol Dis Date: 2005-03 Impact factor: 5.996
Authors: Eloise Kok; Satu Haikonen; Teemu Luoto; Heini Huhtala; Sirkka Goebeler; Hannu Haapasalo; Pekka J Karhunen Journal: Ann Neurol Date: 2009-06 Impact factor: 10.422
Authors: Robert S Wilson; Laurel A Beckett; Lisa L Barnes; Julie A Schneider; Julie Bach; Denis A Evans; David A Bennett Journal: Psychol Aging Date: 2002-06
Authors: Shahram Oveisgharan; Lei Yu; Robert J Dawe; David A Bennett; Aron S Buchman Journal: J Gerontol A Biol Sci Med Sci Date: 2020-03-09 Impact factor: 6.053
Authors: Annah M Moore; Emily Mahoney; Logan Dumitrescu; Philip L De Jager; Mary Ellen I Koran; Vladislav A Petyuk; Renã As Robinson; Douglas M Ruderfer; Nancy J Cox; Julie A Schneider; David A Bennett; Angela L Jefferson; Timothy J Hohman Journal: Neurobiol Aging Date: 2019-11-05 Impact factor: 4.673
Authors: Shahram Oveisgharan; Zoe Arvanitakis; Lei Yu; Jose Farfel; Julie A Schneider; David A Bennett Journal: Acta Neuropathol Date: 2018-10-17 Impact factor: 17.088
Authors: Shahram Oveisgharan; Ana W Capuano; Sukriti Nag; Sonal Agrawal; Lisa L Barnes; David A Bennett; Zoe Arvanitakis; Julie A Schneider Journal: Neurology Date: 2021-04-14 Impact factor: 11.800
Authors: Juliet Fockler; Winnie Kwang; Miriam T Ashford; Derek Flenniken; Joshua Hwang; Diana Truran; R Scott Mackin; Chengshi Jin; Ruth O'Hara; Joachim F Hallmayer; Jerome A Yesavage; Michael W Weiner; Rachel L Nosheny Journal: Alzheimers Dement (N Y) Date: 2021-02-14